Stem Cell Therapy Shows Promise in Early Trial for Type 1 Diabetes

Researchers enrolled 18 patients with Type 1 diabetes in a double-blind, randomized, placebo-controlled trial to test whether cells grown from human gum tissue could help slow or reverse the immune attack that damages insulin-producing beta cells. Half the patients received four intravenous infusions of gum-derived mesenchymal stem cells (GMSCs), given three weeks apart. The other half received placebo infusions. All participants continued their regular insulin therapy throughout the 12-week study.

At 12 weeks, patients who received GMSC therapy showed improvements in C-peptide levels—a measure of how much insulin their own pancreas was still producing. These patients also needed less insulin each day compared to their baseline. Both the GMSC group and placebo group achieved similar overall blood sugar control.

Notably, one patient in the GMSC group stopped requiring insulin entirely after receiving the first treatment. While this is encouraging, it's important to remember this was a single patient in a very small study, so drawing broad conclusions from this one case would be premature.

No serious adverse events were reported. The GMSC group did not have higher rates of low blood sugar episodes or other safety concerns compared to the placebo group. All 18 enrolled patients completed the entire trial.

Laboratory analysis and single-cell sequencing suggested that GMSCs may protect beta cells by activating a process called CD8+ T-cell exhaustion. In Type 1 diabetes, the immune system mistakenly attacks insulin-producing cells. The researchers' findings suggest that GMSCs might dampen this attack by causing the immune cells responsible for it to become 'exhausted'—less able to attack. However, this mechanism is still being studied and requires further research to confirm.

This Phase 1 trial is an important first step in evaluating whether stem cell therapy could help preserve remaining beta-cell function in Type 1 diabetes. The early safety data and signals of benefit are promising, but much larger studies are needed to confirm whether GMSCs truly work and for whom they might be most helpful. Phase 1 trials are designed primarily to test safety and early efficacy in small groups; they are not yet proof that a therapy will work in broader populations.

Source: Signal transduction and targeted therapy. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.